SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Microcap & Penny Stocks : Rat dog micro-cap picks...
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Baton who wrote (39029)1/26/2009 7:01:01 AM
From: Bucky Katt  Read Replies (2) of 48461
 
Maybe, most have already partnered up to some extent with big pharma anyway.

The big pharma deal today might get the mood going though.
(Pfizer Buying Wyeth for $68 Billion)

As usual, there will be spectacular rises in value,
and spectacular crashes in value.

Last week DNDN was cut to an
expectation of the $1 level.

Dendreon - DNDN-NNM
Sell - Price 4.25 on Jan. 20
by Brean Murray Carret & Co.

We reiterate our Sell rating and $1 target, based on our belief that Provenge [prostate-cancer trial] will fail to improve survival in its new Phase 3 Impact trial....We believe $1 is generous, as Dendreon had almost as much debt as cash at 3Q08, and thus should have negative equity in April...[we] believe no new capital will be raised before release of the trial results. Market cap: $412 million.

And we made serious bank on that one, when it was hot...
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News